Moleculin Biotech (LTS:0K2H) COGS-to-Revenue : 0.00 (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Moleculin Biotech COGS-to-Revenue?

Moleculin Biotech's Cost of Goods Sold for the three months ended in Mar. 2025 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2025 was $0.00 Mil.

Moleculin Biotech's COGS to Revenue for the three months ended in Mar. 2025 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Moleculin Biotech's Gross Margin % for the three months ended in Mar. 2025 was N/A%.

Moleculin Biotech COGS-to-Revenue Historical Data

The historical data trend for Moleculin Biotech's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech COGS-to-Revenue Chart

Moleculin Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

Moleculin Biotech Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Moleculin Biotech COGS-to-Revenue Calculation

Moleculin Biotech's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Moleculin Biotech's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Moleculin Biotech (LTS:0K2H) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Moleculin Biotech's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Moleculin Biotech COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Moleculin Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (LTS:0K2H) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

MBRX:USA

Address

5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website

https://www.moleculin.com

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Moleculin Biotech Headlines

No Headlines